• Home
  • About
    • About BNLF
    • Executive Council
    • Early Career Scientists
    • Collaboration
    • Photos
  • News and Events
    • News
    • Our Local Chapter meeting
    • Past meeting -Leiden 2025
    • Worldwide events
    • Webinars
    • Interviews to Luminaries
    • Our Podcast
  • Careers
    • Job offers
    • Grants
  • Join us
    • Join us
    • Contact us
    • Volunteer with us!
  • Plus
    • Home
    • About
      • About BNLF
      • Executive Council
      • Early Career Scientists
      • Collaboration
      • Photos
    • News and Events
      • News
      • Our Local Chapter meeting
      • Past meeting -Leiden 2025
      • Worldwide events
      • Webinars
      • Interviews to Luminaries
      • Our Podcast
    • Careers
      • Job offers
      • Grants
    • Join us
      • Join us
      • Contact us
      • Volunteer with us!

  • Home
  • About
    • About BNLF
    • Executive Council
    • Early Career Scientists
    • Collaboration
    • Photos
  • News and Events
    • News
    • Our Local Chapter meeting
    • Past meeting -Leiden 2025
    • Worldwide events
    • Webinars
    • Interviews to Luminaries
    • Our Podcast
  • Careers
    • Job offers
    • Grants
  • Join us
    • Join us
    • Contact us
    • Volunteer with us!

Koen van der Maaden

Koen van der Maaden is assistant professor in the Tumor Immunology group at the department of Immunology at the Leiden University Medical Center (LUMC). He has a background in Pharmacy and Biopharmaceutical Sciences, and did a PhD on Microneedle-Mediated vaccine delivery. He is co-author of 35 peer-reviewed publications: 31 primary research papers (of which one clinical trial) and 4 reviews and inventor of 5 patents. In his research group he focusses on the development of peptide-based cancer vaccine formulations, fabrication of thermostable intradermal microneedle-based vaccines, and intratumoral delivery devices.

Chamber of commerce number: 74200445

Copyright © 2019 BNLF-crs - All rights reserved


  • Privacy policy
  • Twitter

Optimisé par